SureTrader
Interactive Brokers Advertisement
Home > Boards > Canadian > Biotechs >

Breathtec Biomedical Inc. (BTHCF)

BTHCF RSS Feed
Add BTHCF Price Alert      Hide Sticky   Hide Intro
Moderator: shell3, Diogenes of Sinope, AMG, DiamondInTheRough, smoki, hoyowasobo
Search This Board: 
Last Post: 12/17/2017 12:43:59 AM - Followers: 73 - Board type: Free - Posts Today: 1

 
 


 
September 5th 2017 


Issued and outstanding common shares 54,752,024 

Warrants outstanding 26,029,676 

Stock options outstanding. 3,495,000 


http://thecse.com/sites/default/files/Breathtec_-_CSE_Form_7_-_Monthly_Progress_Report_for_August_2017_-_Completed.pdf
 

http://breathtecbiomedical.com
 

Breathtec Biomedical, Inc. (“Breathtec”) was formed to propel innovative research in the area of breath analysis as a medical screening tool. Our efforts are aimed at leading the development of commercially viable methods for the early screening of diseases such as lung & breast cancers, neurodegenerative diseases (eg: Alzheimer’s / Parkinson’s), tuberculosis, diabetes, liver disease and more.

Our primary avenue of investigation is focused on innovation and advances in the field of specialized mass spectrometry.

The principal market opportunity arises from the potential of low-cost, non-intrusive diagnostic screening in general medical practice which could lead to notable advances in early detection of major cancers and other life-altering diseases.

Regular screening using a simple breath test, could lead to significant advancements in remedial treatment protocols targeting major improvements in survivability and life


 

High-Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS)

Function: Compounds (Ions) are Separated by Mobility

  • Function of the size, shape, charge
    Direct, real-time separation
    Continuous sample introduction

An Ion filter – only molecules of interest are allowed to be detected
[ima][/img]
https://m.youtube.com/watch?v=tBViWFNtZUk

FAIMS Technical Overview

Breathtec Biomedical aims to assist the development of novel instrumentation and methodologies for high-field asymmetric waveform ion mobility spectrometry(FAIMS). FAIMS can be performed on a standalone device, or, more prominently, coupled to a mass spectrometer (MS). FAIMS is a separation technique which allows continuous sample introduction, enabling direct, real-time analysis.

FAIMS (or differential mobility spectrometry, DMS) involves separation based on the inherent differences in an ion’s mobility in high and low electric fields, and can be performed at atmospheric pressure and room temperature

Corporate Presentation
http://3jxjjl3cm6sh2pusp2ofxrx3.wpengine.netdna-cdn.com/wp-content/uploads/2015/10/BreathTec-Corporate-Presentation.pdf

Company filings
http://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00037722



Leadership

Chief Executive Officer

Undecided 


 

Alfred Wong

Vice President, Corporate Development & Communications
2017 - Current 
Breathtec Biomedical, Inc. engages in the provision of medical diagnostic and health-related technology. It involves in the development of commercially viable methods such as of breath analysis screening technologies for the early screening of diseases such as lung, breast cancers, neurodegenerative diseases, tuberculosis, diabetes, liver diseases, and others. The company was founded on January 22, 2015 and is headquartered in Vancouver. Canada.

 


raj

Raj Attariwala, MD, PhD., Lead Engineer

Dr. Attariwala is a dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He received his formal medical training at University of British Columbia with periods of specialized medical training at Memorial Sloan Kettering Cancer Centre (New York), UCLA and USC. He holds a doctorate in Biomedical Engineering from Northwestern University (Evanston, IL).

Dr. Attariwala is a practicing physician in British Columbia and owner of AIM medical imaging. He has pioneered advances in the field of whole body medical imaging and authored numerous publications and presented at international medical conferences on whole body imaging and cancer detection.

Dr. Attariwala has extensively investigated breath testing applications and efficacy in a related role at Cannabix Technologies Inc. where he developed a breath testing system for drug impairment.


yost

Richard A. Yost Ph.D., Scientific Advisor

Dr. Yost, Col. Allen R. & Margaret G. Crow Professor and Head of Analytical Chemistry at the University of Florida received his B.S. degree in Chemistry from the University of Arizona in 1974. In 1975 he pursued an NSF graduate fellowship at Michigan State University focusing on electronics and computerized instrumentation. He received his Ph.D. in 1979 and assumed the position of Assistant Professor at the University of Florida and went on to become head of the Analytical Chemistry Division.

Dr. Yost’s research has involved over 100 graduate students funded by over $40 million in research grants, and has published over 160 papers and 16 patents. Over $30 billion worth of instruments have been sold based on these patents.

He serves as a member of the Florida Board of Governors (Regents) and as the Chair of the Advisory Council of Faculty Senates of Florida. He is past Chair of the UF Faculty Senate and served on the UF Board of Trustees. He served as Treasurer and Secretary of the American Society for Mass Spectrometry, and on the editorial boards of The Journal of the American Society for Mass Spectrometry and The International Journal of Mass Spectrometry.


 


michael

Michael T. Costanzo, Ph.D., Chief Technical Officer

Dr. Costanzo enjoys a passion for science that has directed his career path firmly into the field of analytical chemistry. Over the past five years he has investigated a variety of advanced experimental methodologies and instrumentation with the Yost Research Group at the University of Florida. During this period he utilized UV spectroscopy to help in standardizing procedures for manufacturing respiratory medications, employed novel ion mobility spectrometric techniques and devices to analyze exhaled breath, and performed multiple metabolomics studies of melanoma. Through his efforts, he acquired a vast knowledge of analytical techniques and methodologies and an immense desire for scientific progress.

Previously, Costanzo obtained his Bachelor of Science in chemistry at the State University of New York (Buffalo). During this period he conducted research under Dr. Troy Wood utilizing mass spectrometry to examine products of enzymatic protein digestion in the interest of studying metabolic markers of autism in children. Upon graduation in 2010 he moved to the University of Florida for Ph.D. studies and as a result of his efforts has recently joined with Breathtec Biomedical to propel his own bioanalytical research through the development of revolutionary clinical devices utilizing his background in ion mobility, mass spectrometry, and exhaled breath analysis.

 


 

BREATHTEC BIOMEDICAL INC.
Suite 890, 789 West Pender Street
Vancouver, British Columbia, Canada V6C 1H2 

 

Breathtec Biomedical Provides Corporate Overview

 

-- Company offers update of events and outlook for near term opportunity

 

VANCOUVER, BRITISH COLUMBIA – October 17, 2016 – Breathtec BioMedical, Inc(CSE: BTH.CN) (CNSX: BTH) (CSE: BTH) (XFRA: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases wishes to address recent corporate events and to provide an update regarding its immediate outlook and future plans.

 

In response to recent volatility in its share price, the Company notesthat fluctuations are an example of development stage market volatility which in Management’s opinion should be viewed in the context of the Company’s underlying financial health and strength of its product portfolio. Breathtec maintains a healthy working capital position of $1.3M. Additionally, management of the Company have voluntarily escrowed a significant number of shares with no insider sales having occurred or contemplatedw.

 

Breathtec’s technology portfolio continues to move ahead with all licensing and development agreements in-place and a number of ongoing achievements and development phases underway. A brief summary of recent and ongoing activities is summarized below. 

 

FAIMS Technology:

Breathtec continues to progress its flagship FAIMS technology with the recent completion of a V2 prototype breathalyzer design. The latest design has significant advances over the previous prototype including larger dynamic range and improved efficiency in the square waveform generator, greater sensitivity achievable by the detector, improvements in the design, implementation of the novel ionization source, and is overall more than 10X smaller than the V1 prototype.The current design is well under development and includes features to allow for the addition of an onboard processor, touch screen and rechargeable battery in a handheld device configuration.

 

 

Regulatory Pathway:

Management has engaged regulatory consultants with extensiveexperience in medical device and in vitro diagnostics strategies to evaluate potential regulatory options to propel the FAIMS technology platforms to market. The Company has furtherengaged experienced product development consultants to initiate the design controls, and quality systems processes to meet regulatory approval and to lead the establishment of product manufacturing protocols as a precursor to commercialization.

 

Professional Collaboration:

Dr. Michael Costanzo, Breathtec’s CTO recently gave a well-received presentation Developing a Point-of-Care Device for Breath Analysis Utilizing FAIMS and FAIMS/MS,” to a prestigious group of leading experts in the field of breath analysis in Zurich, Switzerland. At the event, Dr. Costanzo affirmedBreathtec anticipates completion of a prototype of the FAIMS device in Q4 of 2016 and will work alongside our partner to advance the technology towards the clinic.” Dr. Costanzo’s presentation can be found here: http://breathtecbiomedical.com/news/presentations/.

 

Company CEO at the time, Guy LaTorre comments, “We earnestly appreciate the continued interest and support of all our stakeholders, partners, affiliates and shareholders alike. As such, I wanted to take this opportunity to recap our continued technical achievements as we continue to be motivated daily with overwhelmingly positive feedback as regards the need for a Point-of-Care device such as ours as a means to save countless healthcare dollars and untold numbers of lives in the foreseeable future. These factors compel us to move ahead as quickly as possible with this exciting endeavor and we sincerely thank our supporters for the means to do so.”

 

ON BEHALF OF THE BOARD

 

 

For further information, please contact:
Alfred Wong

President & Director

Breathtec BioMedical, Inc





 


 

 

 

SureTrader
Interactive Brokers Advertisement
BTHCF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#2063  Sticky Note Commercial Adoption of Ion Mobility Technology Drives Multi-Omics Application shell3 07/23/17 11:38:00 AM
#2856   Ho Ho !! Brother ...let's go to Kmart smoki 12/17/17 12:43:59 AM
#2855   I'm with you on that shell3 12/16/17 02:32:31 PM
#2854   Get on this Sleigh-ride ... time is right!! smoki 12/16/17 12:13:15 PM
#2853   i dont think we will start the trial hoyowasobo 12/13/17 05:04:54 AM
#2852   im curious about who the next ceo will hoyowasobo 12/13/17 04:49:07 AM
#2851   It sounds to me like Wong is saying AMG 12/12/17 06:21:24 PM
#2850   Sent BreathTec an email Saturday about 3:00 AM shell3 12/12/17 04:40:22 PM
#2849   Some tight trading here....everyone holding their Breath not smoki 12/12/17 03:43:36 PM
#2848   Bring it on BTH!!!!$$&$$&!! smoki 12/12/17 10:07:41 AM
#2847   Hold-on - BTH has orders stacking UP shell3 12/12/17 09:17:17 AM
#2846   I agree and probably more shell3 12/10/17 09:26:06 PM
#2845   Here's some DD that I'm working shell3 12/10/17 09:01:53 PM
#2844   This stock will hit .20 soon enough, Todd JBowsNose 12/10/17 08:50:10 PM
#2840   Eh Hoy O. Follow the threads much? The AMG 12/10/17 12:52:05 PM
#2839   the answer is called pennyland. get real and hoyowasobo 12/10/17 09:37:45 AM
#2838   I beg to differ. The results of a AMG 12/10/17 08:15:00 AM
#2837   This explains why we got out of nanose ILuvblo2 12/10/17 07:09:03 AM
#2836   Follow up: Keeping in mind that Breathtec was AMG 12/09/17 07:48:18 PM
#2835   We can only hope that whatever "news" come AMG 12/09/17 04:24:13 PM
#2834   Think we are waiting on the "Paper smoki 12/09/17 11:44:01 AM
#2833   ~ Awesome Sauce ~ AMG 12/07/17 11:49:46 PM
#2832   Got hit with the fire today....neighborhood/house still in smoki 12/07/17 10:57:30 PM
#2831   Still can't figure out what the 2 million smoki 12/06/17 08:59:21 PM
#2830   I'm out... good luck, peace and prosperity to all. euroconversions 12/06/17 02:32:56 PM
#2829   Enough Already AMG 12/06/17 01:49:04 PM
#2828   Aye Aye, welcome aboard MM3rd. Carthnel 12/06/17 01:37:11 PM
#2827   So, tell us how you really feel. Carthnel 12/06/17 01:35:14 PM
#2826   This my first post to BTHCF board. MM3rd 12/06/17 12:31:35 PM
#2825   Adding another 60M USD Market Valuation would place AMG 12/06/17 10:23:48 AM
#2824   Point taken Carthnel 12/06/17 08:47:33 AM
#2823   That's a crazy discrepancy between blo and bth ILuvblo2 12/06/17 08:36:41 AM
#2822   As we all share our speculation, opinions, and AMG 12/06/17 08:11:03 AM
#2821   I’m on the train of thought “saliva testing Carthnel 12/06/17 07:15:25 AM
#2820   Sad but true Shell- Smoki. My prayers Carthnel 12/06/17 06:27:27 AM
#2819   Monthly is Out shell3 12/06/17 05:19:44 AM
#2818   Thanks AMG ....God's speed to All and hope smoki 12/06/17 12:07:29 AM
#2817   Bullrun Capital Portfolio AMG 12/05/17 11:42:06 PM
#2816   ~ Sending You All The Best Smoki ~ AMG 12/05/17 09:26:36 PM
#2815   Smoky out here in Cali....safe here (southern Cali) smoki 12/05/17 08:54:47 PM
#2814   You must have forgotten about saliva testing north AMG 12/05/17 04:54:19 PM
#2813   I have to admit I was a little Carthnel 12/05/17 03:43:40 PM
#2812   Yep. The Nanose deal was inked well before AMG 12/05/17 03:12:03 PM
#2811   I believe the NaNose deal was done before shell3 12/05/17 02:51:02 PM
#2810   Maybe the focus right now is all on Carthnel 12/05/17 02:44:03 PM
#2809   Shell, IMO, I'm understanding your last two posts AMG 12/05/17 02:14:28 PM
#2808   I just don't see it costing the Company shell3 12/05/17 01:06:21 PM
#2807   The only sure answer I have is a AMG 12/05/17 01:02:50 PM
#2806   Question??? When the FAIMS device is completed how much UCParadise 12/05/17 12:59:19 PM
#2805   One question • Where will Working Capital come from? shell3 12/05/17 12:58:52 PM
#2804   Shareholders here cannot sustain a Reverse Split (RS) AMG 12/05/17 12:29:00 PM
PostSubject